Clinical trial registry record

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated February 18, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06006585
Last registry update
February 18, 2025
Status
Completed
Phase
Phase 1
Sponsor
Boehringer Ingelheim
Enrollment
20
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
20
Population
ALL · 50 Years
Duration
2023-10-06 to 2024-05-24
Intervention
BI 771716
Comparator
Not reported
Outcomes measured
Occurrence of ocular dose limiting events (DLEs) from drug administration until Day 8 — Up to 7 days; Occurrence of drug-related adverse events (AEs) from drug administration until end of study (EOS) — Up to 112 days; Occurrence of any ocular adverse events (AEs) in the study eye from drug administration until EOS — Up to 112 days; Maximum serum concentration of BI 771716 after a single intravitreal (IVT) dose (Cmax) — Up to 84 days; Area under the concentration-time curve of BI 771716 in serum over the time interval from 0 extrapolated to infinity (A…; Time from dosing to maximum serum concentration of BI 771716 (tmax) — Up to 84 days; Trough concentration of BI 771716 in serum — At Day 29; BI 771716 serum concentration — At Day 57
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON